BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Britain Courts Anthropic Amid US Defense Department Dispute 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
 and Lead Plaintiff Deadline - January 3, 2017 - EconoTimes)
NEW YORK, Nov. 10, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed against Cempra Inc. (“Cempra” or the “Company”) (NASDAQ:CEMP) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Cempra between May 1, 2016 and November 1, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
On November 2, 2016, the U.S. Food and Drug Administration reported its preliminary review of Cempra’s drug, solithromycin, to treat community-acquired bacterial pneumonia and specified a significant safety signal for hepatotoxicity. Following this news, Cempra stock dropped $9.71 per share or over 58% to $6.95 on November 2, 2016.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) one of Cempra’s lead product candidates, solithromycin, posed significant safety risks for hepatotoxicity; and (2) consequently, Cempra’s public statements were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/cemp or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Cempra, you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
